Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of PRT7732 in SMARCA4-mutated Solid Tumors
jRCT2031240744Phase 1Active, not recruiting
- Sponsor
- Prelude Therapeutics
- Start
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of PRT7732 in Nonhematologic neoplasms, sponsored by Prelude Therapeutics. Primary endpoints: Dose limiting toxicity of PRT7732, Safety and tolerability of PRT7732 as measured by incidence of DLTs and 4 more. Started Jun 2025; status: active, not recruiting.
02
Drugs
PRT7732
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031240744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240744.